D.E. Shaw & Co
CMTA

D.E. Shaw & Co’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

D.E. Shaw & Co’s Portfolio CMTA Stock Details CMTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-16,026
Closed -$211K – 4114
2018
Q2 		$211K Sell
16,026
-392
-2% -$6.35K ﹤0.01% 3539
2018
Q1 		$249K Buy
+16,418
New +$267K ﹤0.01% 3235

Other funds holding CMTA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

D.E. Shaw & Co's CMTA Position: Q3 2018 in Review

D.E. Shaw & Co sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q3 2018, closing a stake of 16,026 shares — an estimated $211K sold.

D.E. Shaw & Co first reported a position in CMTA in Q1 2018 and held it in 2 quarters. The position peaked at $249K in Q1 2018. 27 funds tracked by Wall St. Rank hold CMTA as of Q3 2018.

  • D.E. Shaw & Co reported no remaining Clementia Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
  • D.E. Shaw & Co sold 16,026 Clementia Pharmaceuticals Inc. shares in Q3 2018, an estimated $211K.
  • D.E. Shaw & Co first reported a position in Clementia Pharmaceuticals Inc. in Q1 2018 and held it in 2 quarters.
  • D.E. Shaw & Co's Clementia Pharmaceuticals Inc. position peaked at $249K in Q1 2018.
  • 27 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q3 2018.

Based on D.E. Shaw & Co's 13F filing for Q3 2018, filed 14 Nov 2018.